SF4419

Purpose

Summarizes changes to Minnesota law aimed at making prescription drug transactions more efficient and transparent. The bill focuses on two major goals: (1) standardizing and speeding up prescription drug prior authorizations through electronic systems, and (2) increasing price transparency by requiring reporting of drug prices, price increases, and other cost-related data by manufacturers, pharmacies, pharmacy benefit managers (PBMs), and wholesale drug distributors. It also creates a process to identify drugs of substantial public interest and sets up data-sharing rules and timelines.

What this bill does (Key Provisions)

• Electronic drug prior authorization (PA) standardization and transmission

  • Establishes a plan to standardize how PA requests are sent between providers and group purchasers, with the aim of simplifying administration and enabling electronic transmissions.
  • Creates a standard guide for electronic exchange (the “transactions companion guides”) that aligns with national standards.
  • Requires that PA requests be submitted electronically (accessible by providers and group purchasers) by certain dates, with final rules using the NCPDP SCRIPT standard by January 1, 2027.
  • Includes rules about when electronic transmission is required and how to handle attachments (facsimile is not considered electronic transmission; paper attachments must be linkable to the electronic claim if used).
  • Addresses group purchasers not covered by HIPAA and allows exemptions if electronic data interchange is not feasible, or if another national standard is more appropriate. Requires yearly review of exemptions and possible rulemaking if exemptions are ended.

• Expanded price transparency and reporting for prescription drugs

  • Creates a framework to identify and publicly list drugs of substantial public interest, with quarterly updates and a limit (not more than 500 drugs per notice).
  • Requires various parties (manufacturers, pharmacies, PBMs, wholesale drug distributors) to report detailed drug pricing and related data. Each group has its own reporting requirements and timelines.
  • Establishes specific data elements to be reported for each drug, including national drug code (NDC), product name, dosage form, strength, package size, prices over time, acquisition costs, rebates, rebates payable/receivable, sales, and related cost data (manufacturing, marketing, distribution), as well as information on patient assistance programs and any agreements affecting generic entry.
  • Requires reporting of top international prices for brand-name drugs (where applicable) and other price-related history (e.g., introductory price, price in prior years, patent status).

• Definitions and scope changes

  • Adds or clarifies definitions for key terms used in price reporting, including biosimilars, brand-name drugs, generics, pricing units, wholesale drug distributors, and prescription drug price terms (e.g., wholesale acquisition cost, new prescription drugs, patient assistance programs).
  • Sets definitions for terms like “substantial public interest” drugs, pricing concepts, and other data elements to be reported.

• Implementation and processes

  • Outlines the timeline for implementing electronic PA standards (early steps in 2010s, with full electronic PA using the national standard by 2027).
  • Specifies how exemptions to electronic reporting will be handled and reviewed.
  • Establishes notice and reporting procedures, including timeframes (often within 60 days of notification to report) and the ability to provide supporting documents.

• Significance to health law landscape

  • Reforms how prescription drug pricing data are collected and disclosed to the state, potentially affecting consumer awareness and policy discussions about drug costs.
  • Tightens the information available to regulators and the public about drug pricing dynamics, including cost components, rebates, and international price comparisons.

Significant changes to existing law

• Electronic PA requirements and standards become central for prescription drug transactions, moving away from paper or non-standard methods toward standardized electronic exchanges (NCPDP SCRIPT) between providers and group purchasers.
• Expanded reporting framework across multiple types of entities (manufacturers, pharmacies, PBMs, wholesalers) with a broad set of data points tied to each drug.
• Introduction of a formal process to identify and monitor drugs of substantial public interest and to trigger additional reporting for those drugs.
• Broad changes to pricing terminology and data collection, including formal definitions of NDC, pricing units, WAC, and related concepts to support standardized reporting.
• Several protections and exemptions for certain group purchasers and for specific transaction types, with annual reviews and potential rulemaking.

Potential impacts

• For providers and group purchasers: clearer, standardized processes for PA may reduce administrative burden and speed up patient access to therapies.
• For patients and consumers: greater transparency about drug prices, price changes, and the drivers of costs.
• For manufacturers, PBMs, pharmacies, and wholesalers: new, detailed reporting obligations could increase compliance requirements and public visibility into pricing, costs, and rebates.
• For policymakers and the public: a richer data set to inform discussions on drug pricing and potential policy actions.

Implementation considerations

• The bill lays out a phased approach, starting with outlining and guide development, then moving to electronic PA standards, and finally mandating nationwide-standard electronic transactions by a specified future date.
• It includes mechanisms for exemptions and reviews to adjust requirements based on feasibility and national standards.

Summary in plain language

• The bill aims to make prescription drug approvals quicker and more consistent by moving to standardized electronic requests and nationwide data formats by 2027.
• It also aims to shine a brighter light on drug prices by requiring regular reporting of prices, price changes, and related cost data from drug makers, pharmacies, PBMs, and wholesalers, with a focus on drugs that are of high public interest.
• It creates a public-facing process to identify drugs of substantial public interest and requires extensive data reporting to support transparency in drug pricing.
• It adds many definitions to ensure clear, uniform reporting and creates a framework for implementing these changes, including exemptions where appropriate.

Relevant Terms - electronic drug prior authorization - prior authorization (PA) - ePA (electronic PA) - NCPDP SCRIPT Standard - electronic data interchange (EDI) - HIPAA - group purchasers - transactions companion guides - standard companion guide - National Drug Code (NDC) - biosimilar - generic drug - brand-name drug - price increases reporting - wholesale acquisition cost (WAC) - pricing unit - prescription drug substantial public interest - reporting period - manufacturers - pharmacies - pharmacy benefit manager (PBM) - wholesale drug distributor - price transparency - patient assistance programs - patent expiration - international price comparisons - acquisition price - claims and eligibility information - top international price paid (for brand-name drugs)